2023-02-01 2024-01-31 false Capium Accounts Production 1.1 13828464 2023-02-01 2024-01-31 13828464 bus:FullAccounts 2023-02-01 2024-01-31 13828464 bus:FRS102 2023-02-01 2024-01-31 13828464 bus:AuditExemptWithAccountantsReport 2023-02-01 2024-01-31 13828464 bus:SmallCompaniesRegimeForAccounts 2023-02-01 2024-01-31 13828464 bus:PrivateLimitedCompanyLtd 2023-02-01 2024-01-31 13828464 2023-02-01 2024-01-31 13828464 2024-01-31 13828464 bus:RegisteredOffice 2023-02-01 2024-01-31 13828464 core:WithinOneYear 2024-01-31 13828464 core:AfterOneYear 2024-01-31 13828464 1 2023-02-01 2024-01-31 13828464 bus:Director1 2023-02-01 2024-01-31 13828464 bus:Director1 2024-01-31 13828464 bus:Director1 2022-01-05 2023-01-31 13828464 2022-01-05 13828464 bus:LeadAgentIfApplicable 2023-02-01 2024-01-31 13828464 2022-01-05 2023-01-31 13828464 2023-01-31 13828464 core:WithinOneYear 2023-01-31 13828464 core:AfterOneYear 2023-01-31 13828464 bus:EntityAccountantsOrAuditors 2022-01-05 2023-01-31 13828464 bus:OrdinaryShareClass1 2023-02-01 2024-01-31 13828464 bus:OrdinaryShareClass1 2024-01-31 13828464 bus:OrdinaryShareClass1 2022-01-05 2023-01-31 13828464 bus:OrdinaryShareClass1 2023-01-31 13828464 core:CostValuation core:Non-currentFinancialInstruments 2024-01-31 13828464 core:CostValuation core:Non-currentFinancialInstruments 2023-01-31 13828464 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2024-01-31 13828464 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2024-01-31 13828464 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2024-01-31 13828464 core:Non-currentFinancialInstruments 2024-01-31 13828464 core:Non-currentFinancialInstruments 2023-01-31 13828464 core:ShareCapital 2024-01-31 13828464 core:ShareCapital 2023-01-31 13828464 core:RetainedEarningsAccumulatedLosses 2024-01-31 13828464 core:RetainedEarningsAccumulatedLosses 2023-01-31 13828464 core:ShareCapitalOrdinaryShares 2023-02-01 13828464 core:ShareCapitalOrdinaryShares 2022-01-05 13828464 core:ShareCapitalOrdinaryShares 2023-02-01 2024-01-31 13828464 core:ShareCapitalOrdinaryShares 2022-01-05 2023-01-31 13828464 core:ShareCapitalOrdinaryShares 2024-01-31 13828464 core:ShareCapitalOrdinaryShares 2023-01-31 13828464 core:RetainedEarningsAccumulatedLosses 2023-02-01 13828464 core:RetainedEarningsAccumulatedLosses 2022-01-05 13828464 core:RetainedEarningsAccumulatedLosses 2023-02-01 2024-01-31 13828464 core:RetainedEarningsAccumulatedLosses 2022-01-05 2023-01-31 13828464 core:RetainedEarningsAccumulatedLosses 2024-01-31 13828464 core:RetainedEarningsAccumulatedLosses 2023-01-31 13828464 dpl:Item1 2023-02-01 13828464 dpl:Item1 2024-01-31 13828464 dpl:Item1 2022-01-05 13828464 dpl:Item1 2023-01-31 iso4217:GBP xbrli:shares xbrli:pure
Registered Number: 13828464


 

 

 

PHARMACY @ HOME LTD


Unaudited Financial Statements
 


Period of accounts

Start date: 01 February 2023

End date: 31 January 2024
Director Arash Nava
Registered Number 13828464
Registered Office 32 Oakwood
Lobely Hill
Newcastle Upon Tyne
Tyne & Wear
NE11 0DE
Accountants Acumen Accounting
364 West Road
Newcastle Upon Tyne
Tyne & Wear
NE4 9JY
1
Director's report and financial statements
The director presents his/her/their annual report and the financial statements for the year ended 31 January 2024.
Principal activities
Principal activity of the company during the financial year end 31 January 2024 was of Dispensing chemist in specialised stores.
Director
The director who served the company throughout the year was as follows:
Arash Nava
Statement of director's responsibilities
The director is responsible for preparing the directors' report and the financial statements in accordance with applicable law and regulations and in accordance with United Kingdom Generally Accepted Accounting Practice.
Company law requires the director to prepare financial statements for each financial year. Under that law the director has elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the director must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and the profit or loss of the company for that period.
In preparing these financial statements, the director is required to :
  • select suitable accounting policies and then apply them consistently
  • make judgements and accounting estimates that are reasonable and prudent
  • state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements and
  • prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.
The director is responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. The director is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
The director is responsible for the maintenance and integrity of the corporate and financial information included on the company's website. Legislation in the United Kingdom, governing the preparation and dissemination of financial statements, may differ from legislation in other jurisdictions

On behalf of the board.


----------------------------------
Arash Nava
Director

Date approved: 17 February 2025
2
Accountant’s report
You consider that the company is exempt from an audit for the year ended 31 January 2024 . You have acknowledged, on the balance sheet, your responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts. These responsibilities include preparing accounts that give a true and fair view of the state of affairs of the company at the end of the financial year and of its profit or loss for the financial year.
In accordance with your instructions, we have prepared the accounts which comprise the Profit and Loss Account, the Statement of Comprehensive Income, the Balance Sheet, the Statement of Changes in Equity and the related notes from the accounting records of the company and on the basis of information and explanations you have given to us.
We have not carried out an audit or any other review, and consequently we do not express any opinion on these accounts.
Acumen Accounting
31 January 2024



....................................................
Acumen Accounting
364 West Road
Newcastle Upon Tyne
Tyne & Wear
NE4 9JY
17 February 2025
3
 
 
Notes
 
2024
£
  2023
£
Current assets      
Cash at bank and in hand 13,804    100 
Creditors: amount falling due within one year 4 (11,137)  
Net current assets 2,667    100 
 
Total assets less current liabilities 2,667    100 
Net assets 2,667    100 
 

Capital and reserves
     
Called up share capital 5 100    100 
Profit and loss account 2,567   
Shareholders' funds 2,667    100 
 


For the year ended 31 January 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:
  1. The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
  2. The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006, the income statement has not been delivered to the Registrar of Companies.
The financial statements were approved by the director on 17 February 2025 and were signed by:


-------------------------------
Arash Nava
Director
4
  Equity share capital   Retained Earnings   Total
£ £ £
Total comprehensive income for the year
Shares issued 100  100 
Total investments by and distributions to owners 100  100 
At 31 January 2023 100  100 
At 01 February 2023 100  100 
Profit for the year 5,731  5,731 
Total comprehensive income for the year 5,731  5,731 
Dividends (3,164) (3,164)
Total investments by and distributions to owners (3,164) (3,164)
At 31 January 2024 100  2,567  2,667 
5
General Information
Pharmacy @ Home Ltd is a private company, limited by shares, registered in , registration number 13828464, registration address 32 Oakwood, Lobely Hill, Newcastle Upon Tyne, Tyne & Wear, NE11 0DE.

The presentation currency is £ sterling.
1.

Accounting policies

Significant accounting policies
Statement of compliance
These financial statements have been prepared in compliance with FRS 102 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.
Basis of preparation
The financial statements have been prepared under the historical cost convention as modified by the revaluation of land and buildings and certain financial instruments measured at fair value in accordance with the accounting policies.
The financial statements are prepared in sterling which is the functional currency of the company.
Turnover
Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts.
Government grants
Government grants received are credited to deferred income. Grants towards capital expenditure are released to the income statement over the expected useful life of the assets. Grants received towards revenue expenditure are released to the income statement as the related expenditure is incurred.
Taxation
Taxation represents the sum of tax currently payable and deferred tax. Tax is recognised in the statement of income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves.
The company’s liability for current tax is calculated using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Current and deferred tax assets and liabilities are not discounted
Dividends
Proposed dividends are only included as liabilities in the statement of financial position when their payment has been approved by the shareholders prior to the statement of financial position date.
2.

Staff Costs

2024
£
  2023
£
Wages and salaries 9,500   
9,500   
 
Average number of employees during the year Number   Number
 

3.

Average number of employees

Average number of employees during the year was 0 (2023 : 0).
4.

Creditors: amount falling due within one year

2024
£
  2023
£
Corporation Tax 1,344   
Directors' Current Accounts 9,793   
11,137   

5.

Share Capital

Allotted, called up and fully paid
2024
£
  2023
£
100 Class A shares of £1.00 each 100    100 
100    100 

6